Promising drug cocktail targets Hard-to-Treat liver cancer

NCT ID NCT05773105

Completed Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a combination of two drugs, cadonilimab and regorafenib, in 36 adults with advanced liver cancer that had worsened after standard treatments. The goal was to see if the combo could slow cancer growth and how safe it was. Results may help develop better options for patients with limited choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cadonilimab and regorafenib
What this could lead to: If successful, this combination could offer a new treatment option for advanced liver cancer patients who have run out of standard therapies.
What could go wrong: This is an early-phase, single-center trial with only 36 participants, so results may not apply broadly. The combination may cause significant side effects and may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma type 1 diabetes mellitus 12

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.